Advisory Advocates’s AbbVie ABBV Stock Holding History

Advisory Advocates’s Portfolio ABBV Stock Details ABBV Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q2	–	Sell	-978	Closed	-$213K	–	189
2026 Q1	$213K	Buy	+978	New	+$217K	0.22%	143

Other funds holding ABBV

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM

State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM

JP Morgan Chase New York $1.81T AUM 41.13% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return

Morgan Stanley New York $1.89T AUM 35.08% 1-Year Est. Return

Capital Research Global Investors Los Angeles, California $717B AUM 35.42% 1-Year Est. Return

Norges Bank Oslo, Norway $1T AUM

Northern Trust Chicago, Illinois $860B AUM 41.15% 1-Year Est. Return

Advisory Advocates's ABBV Position: Q2 2026 in Review

Advisory Advocates sold out of AbbVie (ABBV) in Q2 2026, closing a stake of 978 shares — an estimated $213K sold.

Advisory Advocates first reported a position in ABBV in Q1 2026 and held it in 1 quarter. The position peaked at $213K in Q1 2026. 4,063 funds tracked by Wall St. Rank hold ABBV as of Q2 2026.

Advisory Advocates reported no remaining AbbVie position as of Q2 2026 after selling out during the quarter.
Advisory Advocates sold 978 AbbVie shares in Q2 2026, an estimated $213K.
Advisory Advocates first reported a position in AbbVie in Q1 2026 and held it in 1 quarter.
Advisory Advocates's AbbVie position peaked at $213K in Q1 2026.
4,063 funds tracked by Wall St. Rank held AbbVie as of Q2 2026.

Based on Advisory Advocates's 13F filing for Q2 2026, filed 10 Aug 2026.